Legal experts warn that betting on pharmaceutical outcomes through platforms such as Kalshi and Polymarket introduces new risks of insider trading for private biotech companies. These prediction markets allow participants to wager on the success or failure of drug approvals and other critical events, potentially leading to the misuse of non-public information. This could create an environment where insider trading becomes more prevalent, as individuals with access to confidential data might exploit these platforms for financial gain.
The implications for manufacturers and investors are significant. Companies may need to enhance their compliance measures and monitoring systems to mitigate the risks associated with these betting platforms. Additionally, investors should remain vigilant about the potential for market manipulation as these prediction markets evolve.
Source: pharmaceutical-technology.com · Image: 20110921-FNCS-TEW-0003 – Flickr – USDAgov by U.S. Department of Agriculture, Public domain, via Wikimedia Commons
Use the database as your supply chain compass →
